Biodesix Delivers Strong Q4 and Fiscal 2025 Results

Company reports 41% revenue growth, 83% gross margin, and first-ever Adjusted EBITDA positivity in Q4 2025

Published on Feb. 27, 2026

Got story updates? Submit your updates here. ›

Biodesix, Inc., a leading diagnostic solutions company, announced its financial and operating results for the fourth quarter and fiscal year 2025. The company delivered 41% revenue growth and 83% gross margin in Q4 2025, improved net loss by 52%, and achieved its first-ever Adjusted EBITDA positivity in the quarter. For fiscal year 2026, the company provided revenue guidance of $106-112 million, reflecting 23% growth over 2025.

Why it matters

Biodesix's strong financial performance in 2025, including accelerated revenue growth, improved profitability, and positive Adjusted EBITDA, demonstrates the company's ability to execute on its commercial strategy and capitalize on the growing demand for its diagnostic solutions. The guidance for continued growth and profitability improvement in 2026 suggests the company is well-positioned to maintain its momentum and solidify its leadership in the diagnostic solutions market.

The details

In Q4 2025, Biodesix's Diagnostic Tests core organic revenue, excluding collection on claims older than one year, grew 40% to $24.1 million, driven by a 23% increase in test volumes and higher average revenue per test. The company's Development Services revenue also increased, up 12% to $3.6 million. Total revenue for the quarter was $28.8 million, a 41% increase over the prior year. Gross margin expanded to 83%, and the company achieved its first-ever Adjusted EBITDA positivity of $0.5 million, a $4.5 million improvement from Q4 2024.

  • Biodesix announced its Q4 and fiscal year 2025 results on February 26, 2026.
  • The company provided financial guidance for fiscal year 2026, with revenue expected to be in the range of $106-112 million.

The players

Biodesix, Inc.

A leading diagnostic solutions company that develops and markets tests to support clinical decisions and improve outcomes for patients with lung disease.

Scott Hutton

Chief Executive Officer of Biodesix.

Got photos? Submit your photos here. ›

What they’re saying

“Biodesix delivered exceptional results in the fourth quarter, with revenue of $28.8 million and 83% gross margin.”

— Scott Hutton, Chief Executive Officer (Biodesix press release)

What’s next

Biodesix plans to continue investing in its sales organization, expanding its pipeline, and pursuing new partnerships to drive further growth and profitability in 2026.

The takeaway

Biodesix's strong financial performance in 2025, including accelerating revenue growth, improving profitability, and achieving positive Adjusted EBITDA, positions the company well to capitalize on the growing demand for its diagnostic solutions and maintain its leadership in the market.